Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
Northwestern University
Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Eligibility
- Age range
- 18–70 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Individuals age 18-70 years old with eyelid dermatitis for at least two months * Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) * Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib. * Willing and able participants that provide informed consent * Willing and able participants that comply with study activities Exclusion Criteria: * Self-reported history of allergic response to upa…
Interventions
- DrugUpadacitinib 15 MG
Upadacitinib 15mg daily
Location
- Northwestern University Department of DermatologyChicago, Illinois